Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KiroVAX 004

Next Previous
Drug Profile

KiroVAX 004

Alternative Names: KiroVAX-004; TAPA pulsed dendritic cell vaccine - KiroVAX-004

Latest Information Update: 27 Oct 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 27 Oct 2020 No development reported - Phase-I/II for Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC)
  • 18 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02705703)
  • 07 Mar 2016 Preclinical trials in Solid tumours in USA (SC), before March 2016

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top